Cell Biotech Co Rule of 40
The Rule of 40 of Cell Biotech Co (049960.KQ) as of Oct 17, 2026 is 21.33 %. In the previous year, Rule of 40 was 6.41 % — a change of 232.72% (higher).
Get this data via API
Financial Data API
Rule of 40
21.33 %
YoY
232.72%
Last updated:
Rule of 40 of Cell Biotech Co is 2025 21.33 % . Rule of 40 of Cell Biotech Co was 2024 6.41 % . It decreases by 232.72% higher compared to the previous year.
The Cell Biotech Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
37.09 KRW
Jan 1, 2019
-13.91 KRW
Jan 1, 2020
7.22 KRW
Jan 1, 2021
18.31 KRW
Jan 1, 2022
19.80 KRW
Jan 1, 2023
10.38 KRW
Jan 1, 2024
6.41 KRW
Jan 1, 2025
21.33 KRW
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 21.33 % | +232.72% | |
| 6.41 % | -38.25% | |
| 10.38 % | -47.56% | |
| 19.80 % | +8.12% | |
| 18.31 % | +153.48% | |
| 7.22 % | -151.95% | |
| -13.91 % | -137.50% | |
| 37.09 % | -11.35% | |
| 41.84 % | -23.53% | |
| 54.72 % | -7.76% | |
| 59.32 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cell Biotech Co Stock analysis
What does Cell Biotech Co do? Cell Biotech Co Ltd is a South Korean company based in Gimpo, Gyeonggi-Do, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public through an IPO on December 13, 2002. Its primary focus is on the research, development, and manufacturing of probiotics, particularly lactobacillus-based products. Cell Biotech produces lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines aimed at enhancing immunity and improving digestion. Additionally, the company develops finished products containing LABs, designed for applications such as intestinal health improvement, carcinogen inhibition, and calcium supplementation. These products are distributed both domestically within South Korea and internationally. The company's website is http://www.cellbiotech.com/, providing further information about its operations and offerings. Cell Biotech's activities are centered around biotechnology solutions that support health and wellness through probiotic applications. The firm operates with a focus on research and development to advance its product lines, though specific details about its research initiatives or product names beyond the mentioned categories are not provided. The company's market presence spans both domestic and international channels, reflecting its commitment to delivering probiotic-based health solutions across various markets. Cell Biotech Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Cell Biotech Co stock
Rule of 40 of Cell Biotech Co is 21.33 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Cell Biotech Co
All Key Metrics — Cell Biotech Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth